TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Notes to Consolidated Financial Statements (Continued)
Teva did not identify developments with respect to other reporting units in the second
quarter of 2017 that would trigger a potential impairment of goodwill allocated to these reporting units. However, following the 2016 goodwill impairment, the carrying value of the Rimsa reporting unit equals its fair value. The remaining goodwill
allocated to this reporting unit is approximately $1 billion as of June 30, 2017. See note 3 for further discussion. In addition, with regards to Tevas other activities, which are comprised of its distribution and medical device businesses, a
hypothetical decrease in the fair value of approximately 6% could trigger a potential impairment of its goodwill.
For Tevas other
reporting units, the percentage difference between estimated fair value and estimated carrying value ranged between 34% for Tevas European generics reporting unit and 106% for the specialty reporting unit. In determining the fair value of
Tevas reporting units, it used a discounted cash flow analysis and applied the following key assumptions: expected revenue growth and operating profit margins including an estimate for price erosion and discount rate, among others. If any of
these expectations were to vary materially from Tevas assumptions, Teva could face impairment of goodwill allocated to these reporting units in the future.
For all of Tevas business units a new Chief Executive Officer may make changes to any of the current strategies, which may affect the
assumptions. Any change in key assumptions may potentially result in additional impairment charges on goodwill.
NOTE 8 Earnings (loss) per
Basic earnings and loss per share are computed by dividing net results attributable to Tevas ordinary shareholders by the
weighted average number of ordinary shares outstanding (including fully vested restricted share units (RSUs)) during the period, net of treasury shares.
In computing diluted earnings per share for the three and six months ended June 30, 2016, basic earnings per share were adjusted to take into
account the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans, and convertible senior debentures, using the treasury stock method.
Additionally, for the three and six months ended June 30, 2016, no account was taken of the potential dilution of the mandatory convertible
preferred shares amounting to 59.4 million and 59.2 million weighted average shares, respectively and the accrued dividend to preferred shares amounting to $66 million and $132 million, respectively, since they had an anti-dilutive effect on
earnings per share.
In computing loss per share for the three and six months ended June 30, 2017, no account was taken of the potential
dilution of the assumed exercise of employee stock options and non-vested RSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.
Additionally, for the three and six months ended June 30, 2017, no account was taken of the potential dilution of the mandatory convertible
preferred shares amounting to 59.4 million weighted average shares and the accrued dividend to preferred shares amounting to $65 million and $130 million, respectively, since they had an anti-dilutive effect on loss per share.
NOTE 9 Revenue recognition:
Company recognizes revenues from product sales, including sales to distributors, when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable and collectability is reasonably assured. This
generally occurs when products are shipped and title, risk and rewards for the products are transferred to the customer.
product sales are recorded net of provisions for estimated chargebacks, rebates, returns, prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered
reasonably estimable by Teva, the revenue is deferred to a future period when more information is available to evaluate the impact.
Provisions for chargebacks, rebates including Medicaid and other governmental program discounts, as well as other promotional items, such as
shelf stock adjustments, are included in sales reserves and allowances (SR&A) under current liabilities. These provisions are recognized concurrently with the sales of products. Prompt payment discounts are netted against
Calculations for these deductions from sales are based on historical experience and the specific terms in
the individual agreements. Chargebacks and rebates are the largest components of sales reserves and allowances. Provisions for chargebacks are determined using historical chargeback experience, expected chargeback levels and wholesaler sales
information for new products, which are compared to externally obtained distribution channel reports for reasonableness. Rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant
factors that may affect the payment as well as